Genetic diseases are unique because the underlining Considerable variation is seen in these studies, presumdefect (the mutated gene/protein) can be identified and ably reflecting the specificities of the antibodies and studied even if the pathophysiology of the disorder the preservation, fixation and pre-treatment of tissue. is not understood. In this way our knowledge However, some consensus is evident with higher expresof autosomal dominant polycystic kidney disease sion generally seen in foetal than in adult tissue. In the ( ADPKD) has greatly increased over the last couple foetus tubular epithelial cells stain L, with evidence of of years. The major gene, PKD1 (accounting for 85% expression also in the ureteric bud and the S and of ADPKD cases) was identified in 1994 [1 ] and fully comma shaped bodies of the developing nephron. characterized in the following year [2,3]. Over the past Staining of regions of the Bowman's capsule has also 12 months the rate of progress has continued with the been described with some studies showing tuft identification of a second gene, PKD2 (responsible for glomerular staining [7, 10]. In the adult expression is most of the remaining cases), clues to the mechanism probably more localized to the collecting duct with of disease revealed, and localization of the PKD1 less staining of proximal tubules. The subcellular localprotein, polycystin.
whereas the other had apparently normal kidneys when References last examined at 5 years [13 ] . Any theory of pathogen- described in up to 10% of cysts [9] this proportion 8 . GriÃn MD, Torres VE, Grande JP, Kumar R. appears too low unless the majority of somatic changes
Immunolocalization of polycystin in human tissues and cultured cells. Proc Ass Amer Phys 1996; 108: [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] are missense; a question which needs investigation. Nephrotoxicity of ifosfamide-moving towards understanding the molecular mechanisms Ifosfamide may induce renal Fanconi syndrome ( FS). Unlike other toxin-induced FSs, which resolve followApproximately 60 case reports, predominantly from ing discontinuation of toxin exposure, ifosfamidepaediatric populations, have been published. Incidence induced tubular damage is longlasting and potentially ranges between 1.4 and 5% of ifosfamide-treated progressive. patients, another 15% of patients develop a severe, but
The pathogenesis of FS is not fully understood. In subclinical tubular dysfunction. This FS is typically some metabolic diseases like Lowe's syndrome or observed months or even years following cessation of mitochondrial myopathy, associated FS has been chemotherapy. Only few patients develop symptoms related to a defective energy production within the while still on treatment. For the majority of patients proximal tubular cells. the proximal tubular damage leading to the clinical Ifosfamide and cyclophosphamide are isomeric compicture of renal FS does not resolve over time. On the pounds. Neither FS nor proximal tubular damage of other hand, terminal renal failure in these patients has the above-mentioned type have, however, been not been observed as yet. Reversibility of renal damage reported following cyclophosphamide. has been demonstrated in few patients only.
A direct hint for a diÂerential toxicity of the two Apart from the cumulative ifosfamide dose, plati-drugs comes from studies using cultured proximal num derivatives and a reduction of kidney mass, i.e. tubular cells and measuring membrane voltage and unilateral nephrectomy, have been identified as risk conductance: incubation of these cells with ifosfamide factors. By contrast, methotrexate and gentamicin-induced a significant reversible depolarization and a given between chemotherapy cycles-as well as young decrease in conductance, whereas cyclophosphamide age, are no risk factors in ifosfamide-induced nephro-did not induce any change [3 ] . The authors conclude toxicity [1] . The identification of patients at risk of that these diÂerences in acute eÂects may be involved developing severe nephrotoxicity has not been possible, in diÂerences in long-term toxicity. since investigation of renal function during ongoing Both ifosfamide and cyclophosphamide have to therapy with increasing cumulative doses of ifosfamide undergo hepatic metabolism to form the cytostatically has so far failed to identify any specific predictor of active mustards [4] . Along this pathway, acrolein is increasing ifosfamide-induced renal toxicity. generated. It is toxic to epithelial cells and responsible Skinner et al. [2 ] first pointed out that beside overt for the urotoxicity seen after both drugs. Binding of renal FS most patients treated with high cumulative acrolein by mesna is highly eÂective in reducing ifosfamide doses develop subclinical renal impairment, haemorrhagic cystitis. Consequently, ifosfamide as well primarily located at the proximal tubular site. Distal as cyclophosphamide treatment is always combined tubular as well as glomerular dysfunction are secondary with mesna therapy. to the primary proximal tubular damage. Impairment DiÂerences in the metabolism of the two parent of tubular amino acid transport is the leading renal drugs concern side-chain oxidation, which is of minor symptom of ifosfamide-induced renal damage. importance in cyclophosphamide metabolism. Clinically, the most important manifestation of tubular Consequently the products of this side-chain oxidadysfunction is renal phosphate wasting which is seen tion-especially chloroacetaldehyde-have been specin approximately 30% of patients and which determines ulated to be responsible for the ifosfamide-induced the extent of hypophosphataemia and the resulting nephrotoxicity. Since this diÂerence in metabolism is metabolic bone disease. The aÂected patients may merely a quantitative diÂerence, at least some extent develop rickets, growth failure, fluid and electrolyte of proximal tubular damage should be expected followloss as well as renal tubular acidosis [1] .
ing high doses of cyclophosphamide: this, however, is Few patients have undergone renal biopsies; in these not the case. Hence, diÂerences in side-chain oxidation patients, proximal tubular atrophy was the predominare probably not responsible for the diÂerences in ant finding, while interstitial nephritis was only nephrotoxicity. reported in a single patient.
Both parent drugs are metabolized by the Ifosfamide thus induces toxic proximal tubular cytochrome P-450 system, especially its isoenzymes IIB damage which may lead to overt FS in some patients.
and IIIA [5] . These enzymes are also expressed in the proximal tubular system, so that local metabolism is tard, the ifosfamide mustard alkylates DNA with a higher aÃnity and is eÂective over a prolonged time its urinary loss will result in a decrease of intracellular ATP and finally in energetic failure. [6 ] . This allows diÂerential toxicity of the two mustards In summary, ifosfamide may induce irreversible and to diÂerent cells. Following local tubular metabolism potentially progressive renal tubular damage resulting of ifosfamide, a specific damage to proximal tubular in clinically apparent FS, which is not seen after DNA-either nucleic or mitochondrial-could poscyclophosphamide treatment. The pathophysiology of sibly explain the long-lasting regenerative inability and this side-eÂect may be related to direct toxicity of failure of the energy-dependent functions of these cells.
ifosfamide to proximal tubular cells or to specific The ifosfamide-mesna combination induces glutabinding of the ifosfamide mustard to proximal tubular thione depletion in both plasma [7] and-in a rat DNA, either nuclear or mitochondrial; this could aÂect model-renal tubular cells [8 ] . Glutathione is a ubithe regenerative capacity and energy production of quitous detoxifying system. Its depletion renders any aÂected cells. It may then be related to glutathione cell susceptable to oxidative stress by free radicals.
depletion of ifosfamide-mesna therapy. This depletion The amount of mesna given with ifosfamide is much is more profound in ifosfamide-mesna treatment due higher compared to the dose given with cyclophosto the higher mesna doses used. In addition it is phamide treatment. Since mesna forms an adduct with possibly most eÂective in proximal tubular cells, plasma cysteine, mesna alone will cause glutathione because mesna recirculates through these cells. depletion via cysteine depletion. Consequently, the Decreases of renal tubular toxicity following glycine high mesna doses given together with ifosfamide will and carnitine supplementation in rat models again contribute to a profound loss of the intracellular redox point to interaction with the intracellular glutathione potential. Since the proximal tubular cell is able to pool and to a defective energy production within the reabsorb mesna from the proximal tubule, mesna will proximal tubular cells. Ifosfamide-induced FS-like recirculate through these cells. As a consequence, gluta-FS in the context of mitochondrial myopathies-might thione depletion will be especially severe in proximal thus be related to mitochondrial damage in proximal tubular cells. This fact may thus be crucial for the tubular cells. toxicity at this site.
In a rat model of ifosfamide-induced tubular damage, induced FS was attenuated by pretreatment References with glycine [9] . Glycine depletion alone predisposes lipid synthesis and energy production. into the mitochondria to start the energy production, Introduction responses in younger animals [3] . In the elderly population a similar impairment in plasma renin response to Normal ageing is characterized by changes in the sodium restriction has been noted [1, 2] . The tubular activity or responsiveness of a number of hormonal response to administration of aldosterone is blunted systems, altering homeostatic mechanisms in the eld- [5] , as is the plasma aldosterone response to potassium erly. One such system is the renin-angiotensin system infusion [6 ] . ( RAS), which has classically been considered to be
The changing RAS activity also leads to altered suppressed in ageing. Altered activity of the active responsiveness to blockade of the system. Suppression products of this cascade, angiotensin II (Ang II ), and of the RAS is considered to be a mechanism underlying aldosterone, contribute to the increased incidence of the lesser eÂectiveness of ACE (angiotensin-converting certain fluid and electrolyte disorders in the elderly. In enzyme) inhibitors as antihypertensives in elderly recent years it has become apparent that in addition patients. As discussed below, the salutary eÂects of to the well-known circulating (plasma) RAS, there are ACE inhibitors on renal function and proteinuria may a number of independent, locally regulated tissue renin be blunted in the ageing animal as well [7, 8] . -angiotensin systems, whose activity may not necessarConversely, ageing animals appear to be more sensitive ily parallel that in the systemic circulation. Much less to the renal vasoconstrictor eÂects of Ang II [9, 10] , is known of these tissue systems in ageing, though demonstrating impaired natriuresis and augmented preliminary evidence suggests that further exploration kaliuresis with this manoeuvre [9] . of the systems is warranted.
The systemic RAS in ageing
The renal RAS in ageing
It has long been recognized that plasma renin and Deterioration of renal structure and function is part aldosterone levels fall with advancing age [1] . The of normal ageing. By itself, age-related loss of renal mechanisms of RAS suppression are not yet well function poses little danger. However, this functional defined. Hall and co-workers [2] have postulated loss may be greatly accelerated when functioning that these age-related changes result from the loss nephron number is further reduced by acute renal of nephrons; compensatory hyperfiltration in the failure. Though mechanisms of age-related renal disremaining nephrons leads to increased sodium chloride ease remain poorly understood, there is evidence delivery to the macula densa, with suppression of renin implicating haemodynamic forces in this process. synthesis and release, and therefore reduced formation Ageing Munich-Wistar rats are normotensive, yet of Ang II and aldosterone. Studies in ageing animals develop an age-related reduction in aÂerent arteriolar indicate that both renal renin formation and release resistance. The resultant enhanced pressure transmisare reduced, and that both contribute to the observed sion allows an increase in glomerular capillary pressure fall in plasma renin concentration [3 ] . Few studies [8] . This glomerular capillary hypertension is reminishave attempted measurement of Ang II levels in the cent of other renal diseases, in which it is linked to elderly. Preliminary studies in animals are conflicting stimulation of sclerosing mediators and subsequent as to whether plasma Ang II levels fall in parallel with injury. plasma renin levels. In humans, one study found an Studies in diverse renal diseases have implicated the insignificant decline in plasma Ang II levels with ageing RAS as an eÂector of glomerular and tubular injury. [4 ] , though those subjects were neither numerous nor In ageing rats, ACE inhibitors (whether started early very old.
or late in life) slowed proteinuria and glomerular injury These abnormalities lead to suppression of renin [8] . Similar findings have recently been reported in and aldosterone levels at baseline, but also to impaired other ageing models [11, 12] . Though benefit is apparability to mount appropriate responses to RAS stimuli. ent, the data indirectly suggest that this manoeuvre In ageing animals renal renin release in response to may be slightly less eÂective in the ageing kidney, than in the younger one. This benefit might not have been predicted, given
Correspondence and oÂprint requests to: Sharon Anderson MD, the age-related fall in plasma renin. However, emerging
Division of Nephrology, PP262, Oregon Health Sciences University, does not necessarily reveal the intrarenal changes with Conclusion ageing. Optimal methods for assessing the intrarenal (tissue) RAS remain controversial and elusive. Ageing is known to disrupt many hormonal systems, However, one could postulate that the 'renal' RAS and the RAS is no exception. However, the rapid should, in fact, be considered as two distinct systems. advances in our understanding of the relative roles of According to this construct the vascular RAS consists the plasma vs independent tissue renin-angiotensin of the circulating components and the RAS in the systems have only just begun to be applied to the study renal vasculature (including glomeruli), while the tubu-of ageing. Though the plasma RAS appears to be lar (or tubulointerstitial ) RAS consists of the proximal suppressed with normal ageing, intervention studies in tubules and interstitium. Functional, biochemical, and animals have shown that ACE inhibition may slow preliminary molecular biological data are most consist-age-related deterioration in organ systems, such as the ent with downregulation of the vascular RAS. Both kidney [8, 11, 13 ] and the heart [14]. Further investi-PRC and plasma Ang II fall with ageing [1, 12] . Both gations are warranted to understand the role of these decreased renal renin formation (assessed by renin changes, in hopes of their eventual clinical application. mRNA) and sluggish renal renin release (at least to acute stimuli ) contribute to the age-related fall in PRC.
In addition, ACE activity in the renal vasculature and glomeruli is suppressed in ageing animals [3 ] . As a References result, the renal vasoconstriction in response to exogenous Ang II is enhanced in the ageing kidney [9, In contrast to the vascular RAS, there is some Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system R. A. Rodby Rush Medical College, Chicago, Illinois, USA ical to not treat hypertension in a population of Type II diabetic nephropathy is a leading diagnosis of patients entering ESRD programmes in most of the patients with such a high risk of cardiovascular disease. world [1] . Nephropathy is a dreaded complication that Still, it should be apparent if not obvious that blood aÂects a variable proportion of diabetic patients, which pressure control must remain an integral part of the shortens the life expectancy of the individual while management of type II diabetic renal disease. costing billions of dollars to society. The thrust of Although the FDA labelling for captopril specifies research in nephropathy has been targeted toward the type I diabetes, many clinicians are extrapolating the patient with type I diabetes. This has led to one of the results of these studies to treat patients with type II great success stories in clinical nephrology, the use of diabetes. Are there experimental and clinical data to angiotensin-converting enzyme inhibitors (ACEi) to support this move? There are dissimilarities between slow or arrest the progression of diabetic renal disease type I and II diabetic nephropathy in regard to the [2] [3] [4] [5] [6] . The salutary eÂects of these agents has been presentation, clinical course and histology; however, termed 'renoprotection', referring to the specific protec-these are not two independent diseases [8] . In fact in tion of renal function that these agents provide inde-many aspects they appear identical and might indicate pendent of their eÂect on blood pressure. There are that the salutary eÂects of ACEi apply to the type II several large multicentred, prospective, double-blind, population. Predictions in this regard have been hamplacebo-controlled trials demonstrating renoprotection pered by the fact that the majority of the experimental from ACEi in both incipient and overt type I diabetic models have used insulinopenic animals and may not nephropathy [4] [5] [6] . This has resulted in captopril being mimic the hyperinsulinaemic metabolic state of type II the first pharmaceutical agent approved by the United diabetes.
States Federal Drug Administration ( FDA) specifically
The salutary eÂects of ACEi have been extensively for renoprotection. In animals, where the majority of demonstrated in type I patients with both incipient the experimental work has been done with ACEi and (microalbuminuria) and overt nephropathy [4] [5] [6] . diabetic renal disease, ACEi lower systemic blood Data in patients with type II diabetes is more limited. pressure, intraglomerular pressure, and proteinuria. In the study by Ravid et al. [9] 94 type II diabetic Angiotensin II has growth factor and profibrogenic patients with microalbuminuria were prospectively peptide properties that increase messenger RNA treated with either the ACEi enalapril or placebo for expression for extracellular matrix components. Some 5 years. Study end-points were albuminuria and recipof this eÂect may be mediated by transforming growth rocal serum creatinine. Patients receiving enalapril had factor beta (TGF-b ). ACE inhibitors block these non-an improved clinical course for both end-points. In the haemodynamic eÂects of angiotensin II in addition to patients receiving enalapril, the mean patient 24-h the previously described haemodynamic eÂects, and albuminuria was stable over the 5-year study period: renoprotection may be a result of the inhibition of 143 mg/24 h at study initiation and 140 mg/24 h at both of these diverse mechanisms. study end. Patients receiving placebo had an increase That renal function can be preserved by mechanisms in albuminuria from 123 mg/24 h to 310 mg/24 h. The that are independent of the level of blood pressure reciprocal creatinine fell by 13% in the placebo group (renoprotection) does not mean that the level of blood as compared to a minimal decrease (1%) in the enalappressure can or should be ignored. The earliest data ril group. The mean arterial blood pressure ( MAP) on slowing progression of renal failure in type I was about 3 mmHg lower in the enalapril-treated group diabetes was a result of lowering blood pressure withover the course of the study. This approached but did out the use of ACEi. This work, done over a decade not reach statistical significance (P=0.08). Therefore ago, used hypertensive type I patients in which overt renoprotection appears to be evidenced by this study nephropathy was present and enough time had elapsed in type II patients with microalbuminuria. to determine a rate of loss of renal function. A sub-A similar but smaller study was reported by Lebovitz sequent lowering of blood pressure slowed the rate of et al. [10, 11] which included type II patients with deterioration in renal function [7] . Reports such as microalbuminuria (n=38) and overt nephropathy (n= these are not available for the type II population, nor 46). Patients received either the ACEi enalapril or are they likely to appear since it would now be unethplacebo for 3 years. In the microalbuminuric patients treatment with enalapril was associated with a slower Correspondence and oÂprint requests to: Roger A. Rodby MD, Rush-rate of loss of glomerular filtration rate (GFR) by the Presbyterian St Luke's Medical Center, 1653 W. Congress Parkway, Chicago, IL 60612, USA. urinary clearance of 125I-iothalamate; however, this was in the setting of statistically significant diÂerences eÂect of bradykinin on renal haemodynamics appears to be species dependent [14, 15] . The lack of in blood pressure ( MAP 101 mmHg placebo vs 96 mmHg enalapril ), making it diÃcult to determine cough alone may lead to the eventual replacement of ACEi with angiotensin II antagonists. Before this if renoprotection was responsible for the improved prognosis. There was no diÂerence in the rate of loss occurs, however, eÃcacy must be demonstrated with angiotensin II antagonists similar to that which has of GFR in the overt nephropathy patients receiving either enalapril or placebo.
been shown with ACEi for the diverse conditions that these remarkable agents are applied to. In that regard, Nielsen et al.
[12 ] treated 35 patients with type II diabetes and overt nephropathy with either the ACEi the Collaborative Study Group is now evaluating the angiotensin II antagonist irbesartan in type II overt lisinopril or the beta blocker atenolol for 1 year. Endpoints were GFR determined by plasma clearance of diabetic nephropathy. This multicentred, international trial is the largest diabetic nephropathy study to date. [51Cr] EDTA and proteinuria. The blood pressures were similar in both treatment groups. Although the With the patients in the three arms of the trial receiving either the angiotensin II antagonist irbesartan, the lisinopril group had a greater reduction in proteinuria compared to the atenolol group (49 vs 12%), there CCB amlodipine, or placebo in the setting of equivalent blood pressures, the role of angiotensin II antagonists was no diÂerence in rate of loss of GFR (11.7 vs 11.6 ml/min/year). and the question of renoprotection in overt type II diabetic nephropathy should hopefully be defined. Bakris et al. ical significance (P=0.11). Both of these treatment Introduction evidence, with particular focus on a trend emerging from the current data that could guide further For nephrologists consideration of genetic aspects has research to unravel the mechanisms underlying this long been limited to hereditary disorders due to mutaincreased renal risk and thus to develop more eÂective tions in a single gene such as Alport syndrome or therapeutic strategies for patients at risk. polycystic kidney disease. Nevertheless a more extensive role for genetic risk in renal disease was since long suggested by familial clustering of, for instance, dia-ACE genotype and the prevalence of renal disease betic nephropathy and by racial predisposition to endstage renal disease. Moreover, the rate of long-term Early case-control studies in diabetic patients found renal function loss displays a considerable interindian overrepresentation of the D allele in patients with vidual variability even for patients with the same nephropathy compared to those without nephropathy. diagnosis, whereas the individual rate of long-term Subsequent large studies, however, did not confirm renal function loss is often remarkably constant [1] .
these findings, either in IDDM [8 ] , or in NIDDM This well-known phenomenon may reflect diÂerences [9, 10] , suggesting that the D allele does not aÂect the in the severity of renal damage, but genetic determinsusceptibility to develop nephropathy. Similar observaants of progression rate might provide an additional tions were made in IgA nephropathy [11] [12] [13] . Whereas explanation.
the picture is still far from complete, current evidence Recent developments in molecular genetic techniques seems to indicate that ACE genotype does not aÂect aÂorded new insight into the role of genetic risk in the susceptibility to acquire renal parenchymal disease. common, and presumably polygenic disorders such as Renovascular disease, on the other hand, was found cardiovascular and renal disease. Several polymorphto be associated with the D allele [14 ], which may isms of genes coding for components of the reninreflect its primary vascular genesis. angiotensin-aldosterone system ( RAAS) have been identified. The I/D polymorphism of the ACE gene has drawn a lot of interest as the DD genotype ACE genotype and the progression of renal disease appeared to be an independent risk factor for myocardial infarction and left ventricular hypertrophy, in parInterestingly, prospective studies showed an increased ticular in patients without other cardiac risk factors, rate of renal function loss in DD homozygotes in such as those with normal cholesterol, non-smokers, patients with renal disorders of mixed origin [15] and women [2] . Concomitant polymorphism of the (which was confirmed by a large retrospective study AT 1 receptor potentiates the cardiac risk [3] , providing [16 ] ), in nephropathy in IDDM [17 ] , and in IgA evidence for gene-gene interaction. As DD homozynephropathy [11] . Moreover, in IgA nephropathy the gotes have elevated serum [4 ] and tissue ACE [5] , D allele was overrepresented in patients with renal increased vascular conversion of angiotensin I [6 ] and function deterioration [12, 13] , an association more an increased pressor response to angiotensin I [7] , it prominent in patients without proteinuria or hypertenwas hypothesized that increased angiotensin II formasion [12] , suggesting that, as in cardiac disease, in tion is involved in the increased cardiac risk.
renal disease the D allele may act as an independent The RAAS is not only involved in cardiovascular risk factor. Renal survival was found to be worse in disease but also in renal pathophysiology. Not surpris-DD homozygotes in NIDDM [18] , and in polycystic ingly, therefore, the number of studies on the role of kidney disease [19 ] . ACE genotype in renal disease expands rapidly. There
Thus the D allele is associated with an increased is increasing evidence that the DD genotype is a renal rate of renal function loss. Remarkably, this was found Correspondence and oÂprint requests to: Dick de Zeeuw, Department in a spectrum of renal disorders, although it is still of Clinical Pharmacology, State University, Antonius Deusinglaan 1, unclear whether the risk imposed by the D allele is 9713 AV Groningen, The Netherlands. similar for all types of renal disease [16 ] . In accord * GIDS is part of the research school Groningen Utrecht Institute for Drug Exploration (GUIDE).
with this increased progression rate the D allele was overrepresented in haemodialysis patients [16 ] 
but not during ACE inhibition [28] . The relevance of latter findings may seem discrepant with the above studies. It should be remembered, however, that results these findings for therapeutic eÃcacy and its impact for renal patients, however, remain to be established. from association studies can easily be aÂected by selection bias, for instance due to excess cardiac mortality in DD homozygotes.
How could ACE genotype aÂect the progression of renal disease? ACE genotype and the response to intervention therapy
In spite of the increased cardiac and renal risk in DD homozygotes, remarkably, the D allele is overrepresThe finding of elevated serum and tissue ACE and of ented among healthy centenarians [29] . This strongly increased conversion of angiotensin I in DD homozy-suggests that the D allele as such does not necessarily gotes elicited the hypothesis that these patients might increase morbidity, but that additional factors (genetic particularly benefit from ACE inhibitor therapy. Data or environmental ) are required for the D allele to on ACE genotype as a determinant of the response to aÂect risk profile. ACE inhibition in renal patients, however, are conOnce renal damage is present ACE genotype can flicting. The blood-pressure response to ACE inhibition apparently act as a genetic modifier of the progression in DD homozygotes was either similar [22 ] or impaired of renal disease. What mechanisms could be involved? [23 ] in comparison to II and ID genotype. As to the First, we wish to note that it is unclear whether the antiproteinuric response-a predictor of long-term DD genotype mediates progression of renal disease or renoprotection-in IgA nephropathy Yoshida et al. is rather a progression marker. Be this as it may, the [13 ] found that ACE inhibition reduced proteinuria D allele is associated with progressive renal function only patients with the DD genotype. In another study loss in diverse renal disorders. We therefore suggest from Japan, in proteinuria of diverse origin [24] , the that the mechanism of increased renal risk in DD I allele was associated with a poor antiproteinuric homozygotes entails eÂects on common denominresponse to ACE inhibition as well. In several studies ator(s) of renal function loss. A common pathway is from Europe, however, the antiproteinuric response to assumed to account for progressive renal function loss ACE inhibition in patients with the II/ID genotype regardless the type of initial renal damage. As in this was similar [22 ] or better [23 ] than in DD homozy-pathway the RAAS plays an important role, it is gotes, in non-diabetic and in diabetic patients [25, 26] . tempting to speculate that ACE genotype aÂects proDiÂerences in patient selection, study design, and gression rate by eÂects on RAAS phenotype implicated treatment regimen (e.g. dosage of the ACE inhibitor in this common pathway (e.g. tissue action of and dietary sodium intake) may account for the above angiotensin II ). Such a hypothesis is all the more discrepancies. In addition, diÂerences in genetic back-attractive because this putative mechanism of action ground between Caucasian and Japanese subjects might also be involved in the increased cardiac morbidshould be considered. D allele frequency and the ity in DD homozygotes, thus providing a unifying relationship between ACE genotype and RAAS pheno-hypothesis for the increased renal and cardiac risk. type depend on ethnic factors [27] . As the interaction between ethnic factors and ACE genotype awaits clariDirections for the future fication it would be prudent for the moment not to extrapolate observations from one particular population to another.
The DD genotype is associated with progressive renal function loss in many populations, and moreover, As to long-term renoprotection it is remarkable that the prospective observations of an increased progres-renoprotection is hard to obtain in these patients. How could the present knowledge be turned into therapeutic sion rate in DD homozygotes were made despite adequate blood pressure control with either beta block-benefit? First, it is important to better identify individuals in whom the D allele is likely to exert a ade or ACE inhibition in the non-diabetic patients [15 ] and with ACE inhibition in the diabetic patients [17], deleterious eÂect. Considering the polygenic nature of renal and cardiovascular disease, the evidence for that is, during regimens of proven renoprotective potential. Thus, long-term renoprotection by interven-gene-gene interaction and the growing number of candidate genes (e.g. eNOS, endothelin, IL-1 receptor, tion therapy is harder to achieve in patients with the DD genotype.
and TNF-a) this would require studies in large and well-defined populations. We wish to emphasize, fur-A study in essential hypertension suggests that ACE genotype may aÂect hormonal and tissue respons-thermore, the need for truly prospective studies, i.e. studies where patients are randomized not only accordiveness to diÂerent antihypertensives. During ACE inhibition angiotensin II levels fell only in DD homozy-ing to manifestations of disease and treatment, but also according to genotype. Of note, current knowledge gotes. In this study an increased AT 1 receptor expression on mononuclear leukocytes was found in DD on the eÂects of ACE genotype is derived from studies Nephrol Dial Transplant ( 1997) 1996; 17: 787-794 from association studies. This may introduce selec- Isolated pancreas transplantation ( PTx) exceptional: in non-uraemic patients with hyperlabile/instabile type I diabetes (e.g. control of metabolic problems such as hypoglycemic unawareness) or the presence of two or more diabetic complications defined as: proliferative retinopathy, early nephropathy (GFR>70 ml/min and proteinuria 150-3000 g/24 h), overt peripheral or autonomic neuropathy, and vasculopathy with accelerated atherosclerosis prerequisite: minimal HL-A mismatch, eÂective immunosuppression accepted: in post-uraemic patients with type I diabetes after previous kidney transplant from living or cadaveric donor with stable graft function (serum creatinine <2 mg/dl or GFR>40 ml/min) inferior longterm results due to HL-A non-identity of kidney and pancreas
Simultaneous pancreas and kidney transplantation (P+KTx) accepted: in carefully selected, and especially young (20-40 year-old ) pre-uraemic patients with type I diabetes (GFR<40 ml/min) performed routinely in specialized centers ('pre-emptive' transplantation)
optimal: treatment of choice in most uremic patients with type I diabetes pancreas and kidney graft from the same cadaveric donor contraindications mainly in case of serious cardiovascular complications (e.g. non-correctable coronary artery disease, significant cardiomyopathy or recent myocardial infarction) best chance of patient and graft survival ( kidney and pancreas) as well as quality of life only curative therapy of diabetes Islet transplantation ( ITx) ideal: in principle, but still experimental procedure with limited clinical experience, so far, only very few recipients with longterm insulin independence major problems: insuÃcient islet cell mass, control of immune reactions, drug toxicity Several surgical techniques have been used in the past diabetic nephropathy will be prevented. The other sequeto manage the exocrine secretions including duct lae, retino-, neuro-, and vasculopathy may more or less occlusion, intestinalization, enteric or urinary drainage. improve or at least stabilize, depending on the degree Also, questions of extra-or intraperitoneal, even para-of damage. Recurrence of diabetes (isletitis) due to topic placement as well as portal and systemic venous autoimmune processes has been observed in segmental drainage of the graft were investigated. pancreatic grafts only, and seems to be eÂectively Currently, pancreaticoduodenal transplantation-preventable by adequate immunosuppression. the entire pancreas together with a duodenal segment, A synopsis, reflecting the current views about indicawhich is anastomosed side-to-side to the urinary blad-tion and timing of transplantation in diabetes mellitus der, seems to be the procedure of choice. This technique is given in Table 2 . There is little doubt that all diabetic is associated with a relatively low complication rate, patients with end-stage nephropathy should get the and has the additional advantage of continuous mon-same opportunity and standard of therapy as compared itoring of graft function. Introduction of eÂective to patients with other causes of renal failure, i.e. immunosuppressive protocols, recently including FK maintenance dialysis and kidney transplantation. In 506, has also reduced the incidence and severity of principle, patients with IDDM or type I diabetes can acute rejection.
be considered as potential candidates for pancreas At present, recipients of simultaneous pancreas and transplantation, depending on careful selection as well kidney transplants represent the largest series. Their as the status of renal function. Since reversal of secondactuarial patient and graft survival rates are 92 and ary complications is less predictable than prevention, 79% at 1 year, and 81 and 67% at 5 years, respectively. ideally pancreas transplantation should be performed These results compare favourably with kidney replaceearly in the course of diabetes. ment, and especially with pancreas transplantation
In practice, however, isolated pancreas transplantaalone ( Table 1 ). The major impact on quality of life is tion is still an exception in individual patients with insulin-independence per se, together with establishment of an euglycaemic state. According to several normal or only slightly impaired renal function, when studies the majority of patients stated that dialysis-free metabolic control of diabetes or progression of secondmanagement of immunosuppression was easier than ary complications become a problem. Well accepted managing diabetes and dialysis.
are patients with a previous renal transplant or in a pre-uraemic state. Simultaneous pancreas and kidney transplantation is regarded as optimal, and even the
